AOD 9604 with retatrutide is a research-only stack. Learn what each compound does, how the dosing differs, and why no human trials combine them.
AOD 9604 with retatrutide is a research-only combination that has never been tested together in a published human trial. AOD 9604 is a synthetic fragment of human growth hormone studied for fat metabolism, while retatrutide is an investigational triple-agonist drug that targets GIP, GLP-1 and glucagon receptors. People pair them in theory to stack a lipolysis-focused peptide with a powerful appetite-suppressing injectable, but the combination has no established dose, no interaction data, and unknown risks.
What Is AOD 9604?
AOD 9604 (also written AOD-9604) is a 16-amino-acid peptide modeled on the tail end of human growth hormone, covering residues 176–191. It was engineered to isolate growth hormone's fat-metabolizing effects without its effects on blood sugar or growth.
In lab and animal studies, AOD 9604 stimulates lipolysis and inhibits lipogenesis, meaning it encourages fat breakdown and discourages fat storage. Human trials from the 1990s and 2000s showed only modest weight-loss effects, which is one reason the compound never reached the market as a prescription drug. AOD 9604 is not FDA-approved for human use in the United States.
What Is Retatrutide?
Retatrutide (development name LY3437943) is a single molecule that activates three receptors at once: GIP, GLP-1 and glucagon. In a phase 2 trial published in the New England Journal of Medicine, participants with obesity lost an average of about 24% of their body weight after 48 weeks at the highest dose studied.
That result is why retatrutide draws so much attention, and also why the compound is still experimental. Phase 3 trials are ongoing, and buying it outside a trial usually means purchasing an unregulated research chemical. Retatrutide is not FDA-approved for any indication.
AOD 9604 vs Retatrutide: How They Differ
A side-by-side look at aod 9604 vs retatrutide is really a comparison between a narrow peptide fragment and a multi-receptor drug with dramatic trial results. The two are not substitutes for one another.
| Feature | AOD 9604 | Retatrutide |
|---|---|---|
| Drug class | hGH fragment peptide (176–191) | Triple GIP/GLP-1/glucagon agonist |
| Proposed action | Lipolysis, lipogenesis inhibition | Appetite suppression, slower gastric emptying, higher energy expenditure |
| Approval status | Not FDA-approved for human use | Investigational; not FDA-approved |
| Research dosing | Roughly 250–500 mcg per day in most protocols | 1–12 mg per week in phase 2 trials |
| Human data | Small, older trials with mixed results | Large phase 2 trial; phase 3 in progress |
| Reported side effects | Injection-site reactions; limited data | Nausea, vomiting, diarrhea, constipation, elevated heart rate |
Why People Stack Them — and What's Missing
The rationale is simple: AOD 9604 is marketed as a fat-loss peptide, and retatrutide is the most potent weight-loss drug candidate in development. Stacking them is assumed to combine two different fat-loss pathways.
What's missing is evidence. No published human trial has tested AOD 9604 combined with retatrutide. There is no safety data on how the two interact and no way to know whether side effects multiply. Most of what circulates online about the aod-9604 peptide with retatrutide comes from forum logs and vendor marketing rather than controlled research.
Other Combinations People Research
| Combination | Stated rationale | Evidence level |
|---|---|---|
| aod 9604 and retatrutide | Pair a lipolysis peptide with a triple agonist | No human data |
| aod 9604 with tirzepatide | Pair a lipolysis peptide with a dual GIP/GLP-1 agonist | No human data on the combination |
| aod 9604 with tesamorelin | Combine a fragment with a full-length GHRH analog | Small separate studies only; no combination trial |
Threads about aod 9604 with tirzepatide follow the same logic as retatrutide stacks, since tirzepatide is already FDA-approved for type 2 diabetes and obesity. Comparisons of aod 9604 with tesamorelin, a GHRH analog approved for HIV-associated lipodystrophy, usually focus on visceral fat rather than total body weight. In every case, the combination itself is untested.
Handling and Reconstitution Basics
Both compounds are supplied as lyophilized powders and are mixed with a liquid before use in research settings. Bacteriostatic water is the most common diluent, but stability and solubility vary by formulation.
Questions like how to reconstitute aod 9604 with acetic acid come up because some suppliers recommend a dilute acetic acid solution for peptides that clump or fail to dissolve in plain water. Those protocols typically involve a very low acid concentration, careful measurement, and further dilution, and they should never be improvised. This article is informational only and does not provide dosing or injection instructions.
Storage matters too. Unreconstituted powder is generally kept cold and protected from light, and mixed solutions have a limited shelf life. Buyers should treat unverified vials as unknown content, not as pharmaceutical-grade product.
Safety, Legality, and Sourcing Risks
Retatrutide's trial side effects were mostly gastrointestinal, including nausea, vomiting, diarrhea and constipation, and some participants had increases in heart rate. GLP-1-based drugs carry warnings about thyroid C-cell tumors seen in rodents and are contraindicated for people with a personal or family history of medullary thyroid cancer or MEN2.
AOD 9604 has far less human safety data. Reported issues are mostly injection-site reactions, but long-term effects are not well characterized. AOD 9604 is not FDA-approved for human use in the United States.
Because neither compound is approved for the combinations people discuss, online purchases fall outside FDA oversight. Vials may be underdosed, contaminated, or contain something else entirely. Anyone considering either compound should talk with a licensed healthcare professional first.
Bottom Line
AOD 9604 and retatrutide work through different mechanisms and rest on very different evidence bases. AOD 9604 showed weak results in older human studies and is not approved; retatrutide looks highly effective in trials but remains investigational. Combining them is an experiment, not a protocol, and the risks are unknown.
Frequently Asked Questions
Can you stack AOD 9604 with retatrutide?
No human trial has tested AOD 9604 combined with retatrutide, so there is no established safe dose or interaction data for the pair. Retatrutide itself is still investigational and not FDA-approved, and AOD 9604 is not approved for human use either. Anyone considering the combination should speak with a licensed healthcare professional first.
How much AOD 9604 is used with retatrutide?
There is no established dose for the combination because it has never been studied together. Research protocols for AOD 9604 alone commonly list 250–500 mcg per day, while phase 2 retatrutide trials used 1–12 mg once weekly. Those numbers come from separate studies and should not be treated as a stacking guide.
Is AOD 9604 a GLP-1 drug like retatrutide?
No. AOD 9604 is a modified fragment of human growth hormone studied for fat metabolism, while retatrutide is a triple agonist that activates GIP, GLP-1 and glucagon receptors. They are different drug classes with different mechanisms, side-effect profiles and regulatory status.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.